Docetaxel, cisplatin, and capecitabine (DCX) as perioperative chemotherapy in gastroesophageal adenocarcinoma: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Guido Schumacher(Charité - Universitätsmedizin Berlin), Luisa Mantovani‐Löffler, S Daum(Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie), Ralf‐Dieter Hofheinz(University of Mannheim), A. Florschütz(Städtisches Klinikum Dessau), Michael Kneba(Universitäts Hautklinik Kiel), Dmitry Bichev(Charité - Universitätsmedizin Berlin), Albrecht Kretzschmar(Roche (Switzerland)), Dirk Arnold(Asklepios Klinik Altona)
Journal of Clinical Oncology
May 20, 2010
10.1200/jco.2010.28.15_suppl.4116
Cited by 1

Related Papers

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
|Leukemia|2003|3k
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k